68Ga标记成纤维细胞激活蛋白抑制剂PET/CT对新辅助化疗乳腺癌患者病理反应的早期与晚期预测:一项前瞻性研究
该前瞻性研究纳入22例新诊断并需新辅助化疗的乳腺癌患者,在基线、2周期化疗后及术前1周行68Ga-FAPI PET/CT。7例(31.8%)达病理完全缓解;原发灶ΔSUVmax及TBR在早期和晚期均可预测病理完全缓解。
要点
- 22例乳腺癌患者中7例(31.8%)达病理完全缓解,15例(68.2%)有残留肿瘤。
- 病理完全缓解者PET2和PET3时原发灶SUVmax与TBR绝对值低于未达病理完全缓解者(P<0.05)。
- 原发灶ΔSUVmax预测病理完全缓解的AUC在2周期化疗后为0.890、术前为0.978。
核心结论
- 68Ga-FAPI PET/CT评估新辅助化疗期间早期摄取变化可预测乳腺癌患者病理完全缓解及原发肿瘤同心圆退缩。
- 68Ga-FAPI PET/CT在乳腺癌新辅助化疗病理反应的早期和晚期预测方面具有很大潜力。
研究设计与样本
- 前瞻性纳入22例新诊断乳腺癌并有新辅助化疗指征的连续患者,均接受标准化疗。
- 所有患者在基线、2周期新辅助化疗后(PET2)及术前1周(PET3)行68Ga-FAPI PET/CT。
- 测量原发肿瘤区域及阳性区域淋巴结的SUVmax,并用免疫组化分析原发灶成纤维细胞激活蛋白表达。
主要发现
- 7例(31.8%)达病理完全缓解,15例(68.2%)有残留肿瘤;13例(59.1%)原发肿瘤呈同心圆退缩,9例(40.9%)呈弥漫性退缩。
- PET2与PET3之间原发肿瘤ΔSUVmax显著相关(R²=0.822;P=0.001),转移淋巴结ΔSUVmax亦显著相关(R²=0.645;P=0.002)。
- 病理完全缓解者PET2和PET3时原发灶SUVmax与TBR绝对值低于未达病理完全缓解者(P<0.05),任一时间点较大的ΔSUVmax与病理完全缓解强相关(P<0.05)。
- 原发肿瘤退缩模式中观察到SUVmax、TBR和ΔSUVmax相似的下降趋势。
- 免疫组化显示68Ga-FAPI PET/CT的SUVmax和TBR与成纤维细胞激活蛋白表达正相关(两者P<0.001)。
关键数值与推荐
- 预测病理完全缓解的原发灶最佳截断值:2周期化疗后ΔSUVmax为3.4(AUC 0.890),术前ΔSUVmax为1.1(AUC 0.978)。
- 预测病理完全缓解的原发灶最佳截断值:2周期化疗后TBR为-63.8%(AUC 0.879),术前TBR为-90.8%(AUC 0.978)。
- 预测病理完全缓解的原发灶TBR最佳截断值:2周期化疗后为7.6(AUC 0.848),术前为1.4(AUC 0.971)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
68Ga-labeled fibroblast activation protein inhibitor (68Ga-FAPI) PET/CT has demonstrated promising clinical results, with a higher SUVmax and tumor-to-background ratio (TBR) in breast cancer (BC) patients than 18F-FDG PET/CT. Here, we aimed to evaluate the suitability of 68Ga-FAPI PET/CT for the early and late prediction of the pathologic response to neoadjuvant chemotherapy (NAC) in BC. Methods: Twenty-two consecutive patients with newly diagnosed BC and an indication for NAC were prospectively included. All patients underwent standard chemotherapy and 68Ga-FAPI PET/CT at baseline, after 2 cycles of NAC (PET2), and 1 wk before surgery (PET3). SUVmax was measured in the primary tumor region and positive regional lymph nodes. The expression of fibroblast activation protein in the primary lesion was analyzed by immunohistochemistry. Results: Seven patients (31.8%) achieved a pathologic complete response (pCR), and 15 (68.2%) had residual tumors. Thirteen patients (59.1%) showed concentric withdrawal of the primary tumor, and 9 (40.9%) showed diffuse withdrawal. Between PET2 and PET3, the ΔSUVmax of the primary tumor (R 2 = 0.822; P = 0.001) and metastatic lymph nodes (R 2 = 0.645; P = 0.002) were significantly correlated. The absolute values of SUVmax and TBR at PET2 and PET3 were lower in patients with pCR than in those without pCR (P < 0.05). Moreover, a larger ΔSUVmax at any time point was strongly associated with pCR (P < 0.05). Similar downward trends in SUVmax, TBR, and ΔSUVmax were observed in the pattern of primary tumor reduction. For predicting pCR, the optimal cutoff values for ΔSUVmax after 2 chemotherapy cycles, ΔSUVmax before surgery, TBR after 2 chemotherapy cycles, and TBR before surgery of the primary tumor were 3.4 (area under the curve [AUC], 0.890), 1.1 (AUC, 0.978), -63.8% (AUC, 0.879), -90.8% (AUC, 0.978), 7.6 (AUC, 0.848), and 1.4 (AUC, 0.971), respectively. Immunohistochemistry showed that the SUVmax and TBR of 68Ga-FAPI PET/CT were positively correlated with fibroblast activation protein expression (P < 0.001 for both). Conclusion: Assessment of early changes in 68Ga-FAPI uptake during NAC by 68Ga-FAPI PET/CT can predict pCR and primary tumor concentric withdrawal in BC patients. 68Ga-FAPI PET/CT has great potential for the early and late prediction of the pathologic response to NAC in BC.
引用
- Chen L, Zheng S, Chen L, et al. 68Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT for the Early and Late Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Prospective Study. J Nucl Med. 2023. PMID: 37918866. doi:10.2967/jnumed.123.266079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。